- $7.94bn
- $8.06bn
- $1.16bn
- 92
- 18
- 53
- 55
Annual balance sheet for BIO-TECHNE, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 271 | 232 | 247 | 204 | 153 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 123 | 145 | 195 | 218 | 241 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 521 | 511 | 606 | 621 | 617 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 248 | 282 | 289 | 325 | 342 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 2,028 | 2,263 | 2,295 | 2,639 | 2,704 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 107 | 152 | 176 | 129 | 159 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 646 | 700 | 593 | 672 | 635 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 1,381 | 1,563 | 1,702 | 1,967 | 2,069 |
Total Liabilities & Shareholders' Equity | 2,028 | 2,263 | 2,295 | 2,639 | 2,704 |
Total Common Shares Outstanding |